Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr;15(2):309-318.
doi: 10.14740/wjon1832. Epub 2024 Mar 21.

Role of Postoperative Radiotherapy on High-Risk Stage pIIIA-N2 Non-Small Cell Lung Cancer Patients After Complete Resection and Adjuvant Chemotherapy: A Retrospective Cohort Study

Zu Yi Chen  1 , Huan Wei Liang  2 , Yang Liu  2 , Wei Huang  2 , Xin Bin Pan  2
Affiliations

Role of Postoperative Radiotherapy on High-Risk Stage pIIIA-N2 Non-Small Cell Lung Cancer Patients After Complete Resection and Adjuvant Chemotherapy: A Retrospective Cohort Study

Zu Yi Chen et al. World J Oncol. 2024 Apr.

Abstract

Background: The aim of the study was to assess the effectiveness of postoperative radiotherapy in high-risk patients with stage pIIIA-N2 non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy.

Methods: Data from NSCLC patients within the Surveillance, Epidemiology, and End Results (SEER) database were analyzed. The study examined the association between lymph node ratio (LNR) and both cancer-specific survival (CSS) and overall survival (OS) using restricted cubic spline curves. Patients were categorized into high- and low-risk groups based on established LNR cut-off values, and survival outcomes were compared between those receiving postoperative radiotherapy and those who did not within the high-risk group.

Results: The study included 1,690 patients. An LNR threshold of 0.29 was identified for both CSS and OS. Patients with an LNR ≥ 0.29 demonstrated significantly worse CSS (hazard ratio (HR) = 1.56, 95% confidence interval (CI): 1.37 - 1.78; P < 0.001) and OS (HR = 1.44, 95% CI: 1.28 - 1.62; P < 0.001) compared to those with an LNR < 0.29. In the high-risk group (LNR ≥ 0.29), postoperative radiotherapy did not significantly affect CSS (HR = 0.98, 95% CI: 0.82 - 1.17; P = 0.809) or OS (HR = 0.95, 95% CI: 0.81 - 1.11; P = 0.533).

Conclusions: LNR is a significant prognostic factor in patients with stage pIIIA-N2 NSCLC post complete resection and adjuvant chemotherapy. A higher LNR (≥ 0.29) is associated with poorer CSS and OS. However, postoperative radiotherapy does not confer survival benefits in these high-risk patients. Our findings suggest that postoperative radiotherapy should not be routinely performed in this subgroup. Further research is required to explore effective treatment strategies for these patients.

Keywords: Lymph node ratio; Non-small cell lung cancer; Postoperative radiotherapy; Stage pIIIA-N2.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flowchart illustrating the patient selection process for the study, outlining the criteria for inclusion and exclusion from the Surveillance, Epidemiology, and End Results database. SCC: squamous cell carcinoma. AC: adenocarcinoma.
Figure 2
Figure 2
Graphs showing the association between lymph node ratio and survival outcomes, which are analyzed using restricted cubic spline regression models. (a) Cancer-specific survival. (b) Overall survival. HR: hazard ratio; CI: confidence interval.
Figure 3
Figure 3
Kaplan-Meier survival curves comparing cancer-specific survival and overall survival between patients categorized by lymph node ratio: those with lymph node ratio < 0.29 versus lymph node ratio ≥ 0.29. (a) Cancer-specific survival. (b) Data on overall survival. LNR: lymph node ratio; HR: hazard ratio; CI: confidence interval.
Figure 4
Figure 4
Results of multivariate regression analysis assessing various prognostic factors impacting treatment outcomes. (a) Cancer-specific survival. (b) Overall survival. LNR: lymph node ratio.
Figure 5
Figure 5
Kaplan-Meier survival curves depicting treatment outcomes between non-radiotherapy and radiotherapy groups in patients with lymph node ratio ≥ 0.29. (a) Cancer-specific survival. (b) Overall survival. HR: hazard ratio; CI: confidence interval.
Figure 6
Figure 6
Multivariate regression analysis evaluating various prognostic factors for treatment outcomes in patients with lymph node ratio ≥ 0.29. (a) Cancer-specific survival. (b) Overall survival. LNR: lymph node ratio.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708. - DOI - PubMed
    1. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF. et al. Asian thoracic oncology research group expert consensus statement on optimal management of stage III NSCLC. J Thorac Oncol. 2020;15(3):324–343. doi: 10.1016/j.jtho.2019.10.022. - DOI - PubMed
    1. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS. et al. NCCN guidelines insights: non-small cell lung cancer, Version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–266. doi: 10.6004/jnccn.2021.0013. - DOI - PubMed
    1. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, Grodzki T. et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–727. doi: 10.1016/S1470-2045(06)70804-X. - DOI - PubMed
    1. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J, International Adjuvant Lung Cancer Trial Collaborative G. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350(4):351–360. doi: 10.1056/NEJMoa031644. - DOI - PubMed

LinkOut - more resources